QPPV.COM KNOWLEDGE ASSESSMENT

Daratumumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Daratumumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best explains why daratumumab has a therapeutic window despite CD38 being present on some normal cells?
Question 2 of 10 A pharmacovigilance report claims that a patient's response must have resulted specifically from antibody-dependent cellular cytotoxicity. What is the most appropriate interpretation?
Question 3 of 10 A safety database contains a cluster of transfusion delays coded as laboratory abnormalities, with no product term recorded. What is the most appropriate signal-detection response?
Question 4 of 10 Which statement best describes the role of product and batch traceability for daratumumab?
Question 5 of 10 A persistent IgG kappa band is observed during treatment and is interpreted as treatment failure. Which additional assessment is most appropriate?
Question 6 of 10 Which case detail would be most important when evaluating a suspected administration-related reaction to daratumumab?
Question 7 of 10 Which case description provides the strongest basis for assessing suspected loss of efficacy?
Question 8 of 10 Which comparison best illustrates why route should be retained in daratumumab safety analyses?
Question 9 of 10 Which operational control most directly reduces the risk of a transfusion-related delay caused by daratumumab?
Question 10 of 10 Which finding would most specifically support hepatitis B reactivation rather than newly acquired hepatitis B infection?

Select an answer to continue.

QPPV.com